Skip to main content

Table 1 Baseline demographics at index

From: Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma

Demographics

SCS use cohort

N = 7473

Non/burst-SCS use cohort

N = 89,281

Standardized difference (%)

Observation period, months, mean (SD) [median]

24.6 (14.9) [21]

24.2 (15.1) [20]

2.4

Age, years, mean (SD) [median]

67.4 (13.6) [69]

52.2 (20.6) [55]

86.8*

Female, n (%)

4682 (63)

59,249 (66)

7.8

Region, n (%)

   

South

3246 (43.4)

37,373 (41.9)

3.2

West

1664 (22.3)

21,869 (24.5)

5.3

Midwest

1514 (20.3)

18,700 (20.9)

1.7

Northeast

1046 (14.0)

11,225 (12.6)

4.2

Unknown

3 (0.0)

114 (0.1)

3.0

Insurance plan type, n (%)

   

Medicare

5877 (78.6)

37,283 (41.8)

75.4*

Commercial

1596 (21.4)

51,998 (58.2)

75.4*

Physician specialty†, n (%)

   

Primary care

3502 (46.9)

52,432 (58.7)

23.8*

Respiratory specialist

1314 (17.6)

18,193 (20.4)

7.1

Pulmonologist

1070 (14.3)

10,409 (11.7)

7.9

Allergist

247 (3.3)

7839 (8.8)

23.0*

  1. *Standardized difference ≥ 10%; †based on the latest medical claim ≤ 30 days pre-index (inclusive). Includes generalist, internal medicine, pediatrician, and nurse practitioner. Allergist and pulmonologist are not mutually exclusive as patients may visit both specialists on the same day. SCS, systemic corticosteroid